Introduction {#S1}
============

Obsessive-compulsive disorder (OCD) is a psychiatric condition characterized by persistent, intrusive, senseless thoughts and urges (obsessions) and repetitive, intentional behaviors (compulsions). Affected individuals tend to recognize that their thoughts and behaviors are excessive and unreasonable, and often struggle to resist them. The lifetime prevalence of OCD is estimated to be between 1--3%, based on national and international population-based surveys ^[@R1],\ [@R2]^. Patients experience a chronic or episodic course with exacerbations that can substantially impair social, occupational, and academic functioning; according to the World Health Organization, OCD is among the most disabling medical conditions worldwide ^[@R3]^.

Since the early twentieth century, clinicians have suspected that heredity plays an important role in OCD susceptibility. Consistent with this, increased OCD prevalence was identified among first-degree relatives of case probands (11.7%), compared to relatives of controls (2.7%; the Hopkins OCD family study) ^[@R4]^. In the same study, the prevalence of OCD in siblings of early onset probands was 17.9% (λsib =7.8) and thus within the range found in other psychiatric disorders for which a heritable component was reported, such as bipolar disorder and panic disorder. Family studies of child and adolescent OCD probands report prevalence rates of 7% to 15% in first-degree relatives, and 20--30% of these probands had one or more first-degree relative with OCD ^[@R5]^. These findings are consistent with previous reports of an increased familial loading in probands with early age at onset. In addition, a recent population-based study suggested that (while there is no significant effect of a shared environment on OCD risk) the contribution of genetic factors to OCD risk is as high as 50% ^[@R6]^.

Two genetic linkage studies of OCD have found a suggestive linkage peak on chromosomal region 9p24 ^[@R7],\ [@R8]^. The OCD Collaborative Genetics Study (OCGS) also found suggestive genetic linkage peaks on chromosomal regions 3q27-28, 6q, 7p, 1q, and 15q, but none were genome-wide significant ^[@R9]^.

There have been numerous candidate gene association studies in OCD ^[@R10]^. A positional candidate of particular interest is the *neuronal and epithelial glutamate transporter* gene (*SLC1A1*). It is located in the region of the replicated linkage peak on chromosome 9p24, and there is considerable evidence from imaging, animal, and treatment studies that abnormal glutamatergic transmission may be involved in the pathophysiology of OCD ^[@R11],\ [@R12]^. Several studies have reported positive associations of OCD with this gene, but with different SNPs in each ^[@R13]--[@R19]^. A recent meta-analysis of these studies did not resolve the issue and was not able to report experiment-wise significance for SNPs annotated to *SLC1A1* ^[@R20]^.

A genome-wide association study was recently completed by the International OCD Foundation Genetic Collaborative (IOCDF-GC) ^[@R21]^ with a combined study sample from 22 sites, comprising 1 465 cases and 5 557 ancestry-matched controls, as well as 400 complete trios. In case-control analyses, the lowest *P*-values were found for two *SNPs* in perfect LD (rs11081062 and rs11663827; r^2^=1, D′=1 in reference samples from the 1000 genomes project ^[@R22]^; *P*=2.49×10^−6^ and *P*=3.44×10^−6^) Both were located on chromosome 18 within the *discs, large (Drosophila) homolog-associated protein 1* gene (*DLGAP1)*, a member of the neuronal postsynaptic density complex. In the trio analysis, a SNP near the *BTB (POZ) domain containing 3* gene (*BTBD3;* rs6131295, chromosome 20), exceeded the genome-wide significance threshold with a *P*-value=3.84×10^−8^. However, when trios were meta-analyzed together with the case-control samples, the *P*-value for this variant was 3.62×10^−5^, losing genome-wide significance. Although no SNPs were found to be associated with OCD at a genome-wide significant level in the combined trio--case--control sample, a significant enrichment of methylation QTLs (*P*\<0.001) and frontal lobe expression quantitative trait loci (eQTLs) (*P*=0.001) was observed within the top-ranked SNPs (*P*\<0.01) from the trio--case--control analysis, potentially pointing to a broad role in gene expression in the brain, and possibly in the etiology of OCD.

In this paper, we report the results of the most recent genome-wide association study of OCD, the OCD Collaborative Genetics Association Study (OCGAS). Investigators at 8 research centers in the United States, including Brown University, Columbia University, Johns Hopkins University, Massachusetts General Hospital, Harvard School of Public Health, the National Institute of Mental Health, University of California Los Angeles, and the University of Southern California, conducted this collaborative study. The aim of the study was to identify common variants associated with OCD using an integrative analyses pipeline that involved association testing at both SNP and gene levels. The approach included OCD-affected patients (in a family-based analytic setting) with an early onset of the disorder (eighteen years and younger) who had been comprehensively assessed via an identical diagnostic approach at all recruitment centers.

Materials and methods {#S2}
=====================

Sample {#S3}
------

A total of 1 065 families were included in this study (comprising 1 406 patients with OCD and 2 895 individuals in total); 621 families were recruited and assessed specifically for this study at one of the five participating recruitment sites or the National Institute of Mental Health; 444 families had previously been evaluated in one of the earlier studies at Hopkins University or by one of the collaborating sites. The sample comprised of 460 complete trios (including an affected proband and both parents); 155 pedigrees with a proband and an unaffected sibling and 450 families with another structure (complex family structure). An additional 192 probands without an additional family member present in the study (singletons) were included. A breakdown of the families by site is found in [Supplementary Table S1](#SD2){ref-type="supplementary-material"}.

For study inclusion, probands were required to meet DSM-IV criteria for OCD ^[@R23]^ with onset of obsessions and/or compulsions before the age of 18 years (mean = 9.4 years; SD=6.35). Subjects disease, schizophrenia, severe mental retardation that does not permit an evaluation to characterize the psychiatric disorder, Tourette disorder (TS), or OCD occurring exclusively in the context of depression (secondary OCD) were excluded. In addition, individuals were removed from the sample if they were previously diagnosed with brain pathology including brain tumors, Huntington's Disease, Parkinson's Disease, or Alzheimer's Disease. Each case was evaluated by a PhD-level clinical psychologist using the Structured Clinical Interview for DSM-IV (SCID) modified and extended to include additional symptom and diagnostic information as indicated in the [supplementary material](#SD1){ref-type="supplementary-material"}. Final diagnostic status was assigned based on the consensus of two psychiatrists or psychologists reviewing the case independently. Both parents of the proband were also recruited whenever possible. When parents were unavailable for participation, unaffected siblings were recruited. Genotyping was performed at the Johns Hopkins SNP Center using Illumina's HumanOmniExpress bead chips (Illumina Inc., San Diego, CA, USA). More details on the diagnostic assessment and the genotyping process are provided in the [supplementary materials and methods](#SD1){ref-type="supplementary-material"}.

To increase the power of the study to detect significant association, we also included 1 984 unrelated controls (genotyped with Illumina's HumanOMNI1-QUAD bead chip) from a previously published study on Parkinson's disease (dbGaP accession number phs000196.v2.p1) ^[@R24],\ [@R25]^. Individuals with a self-reported or diagnosed neuropsychiatric disorder at the time of enrollment were excluded from the present study.

Quality control of genotyping data {#S4}
----------------------------------

We followed a stringent quality control (QC) protocol that was designed to minimize occurrence of false positive signals, which included checking the relatedness of samples (i.e. verifying the relationship reported from the participating clinical centers) and reported sex (based on deviations from expected heterozygosity rates based on x-chromosomal markers in the analysis; PLINK standard parameters were used). In addition, evidence for genotyping errors at the sample / marker level was evaluated by searching for an excess of "Mendelian inconsistencies" in the data (as indicated by substantial deviation from the empirical distributions in both measurements). Multidimensional scaling (MDS) analyses were performed on singleton OCD cases and unselected controls, as implemented into Plink ^[@R26]^. Samples were removed when they significantly deviated in the first two MDS dimensions (\> 4 standard deviation from the mean). Although inherently robust against population stratification, substantial heterogeneity in the population-based study cohorts would have lead to decreased power for our analytical approach (see below). More details on the QC process are provided in the [supplementary materials and methods](#SD1){ref-type="supplementary-material"} section. Use of the described filters resulted in a final analysis dataset comprising 5 061 individuals from the OCGAS samples and additional controls, with available genotypes for 549 123 autosomal markers.

Statistical analyses {#S5}
--------------------

For the single-marker association analyses, we used a recently published method for combining family-based and population-based data. More precisely, family-based association testing of within-family information is combined with population-based analyses of between-family information and the association analyses of unrelated study subjects ^[@R27]^. This hybrid approach is inherently robust to population stratification and potentially increases statistical power compared to a classic meta-analysis design ^[@R27]^. As part of our analytical pipeline we therefore computed *P*-values for all autosomal markers and both the within and the between family information using PBAT ^[@R28]^. The two *P*-values were subsequently combined using a weighted Z-score statistic as implemented via METAL ^[@R29]^.

Gene-based statistics were derived as fixed Z scores, as implemented in FORGE ^[@R30]^. More information on the approach is provided elsewhere ^[@R31]^. Here we used the single-marker results of our combined OCGAS GWAS. Information about the correlation pattern in the data was provided through usage of HapMap phase 2 samples ^[@R32]^. A maximum of 1 000 000 permutations were used per gene (adaptive approach) and analyses included an additional +/− 20kb sequence information based on positions obtained from ENSEMBL v70 ^[@R33]^. We used the gene-based results in two ways: First we used them to agnostically search for genes that are associated with OCD. Second, we used them to follow-up on gene-set based results from the IOCDF-GC study, which reported an enrichment of association signals for two gene sets that comprised high confidence targets of two miRNA families ^[@R21]^. In addition, we used information from a global interactome for Homo sapiens in order to identify high confidence interactors of DLGAP1 and GRIK2 (confidence threshold \> 0.95) ^[@R34]^. No sub-network reduction was applied and only genes representing first neighbors of *DLGAP1* and/or *GRIK2* in the global interactome were considered for this analysis. We used gene-based results in order to identify an enrichment of association with OCD in interaction partners of DLGAP1 and the ionotropic kainate 2 glutamate receptor (GRIK2). This analysis was motivated by the assumption that biologically closely related genes of these previously described OCD risk genes would make reasonable candidates for hypothesis driven downstream analyses. Based on an assumed similarity between these genes with regards to an involvement in common biological processes and provided that, on a broader level, these biological processes themselves are associated with the phenotype under study it seems reasonable to hypothesize that focusing on biologically closely related genes (see above) helps to identify new disease genes (through reduction of some of the multiple testing burden in standard GWAS). More information on the usage of the interactome data and the visualization of the resulting networks are found in the [supplementary material and methods](#SD1){ref-type="supplementary-material"}. In brief, we would like to emphasize that our analyses represent a simple, hypothesis driven approach for inclusion of the human interactome data, rather than an exhaustive network science approach (making use among others of topological features of the interactome other then the status of direct interaction). While the latter has been successfully used with neuropsychiatric traits in the past, we felt that this evolving field still needs some further improvements and therefore decided to refrain from these kinds of analyses.

Results {#S6}
=======

Single SNP association {#S7}
----------------------

Analysis of the 549 123 autosomal markers revealed a nominally significant result at the level of α=0.05 for 27 283 markers. Among these, 456 markers reached a *P*-value of less than 0.001 and 54 markers were identified with a *P\<*0.0001. As expected due to the stringent study design, no evidence for population stratification was observed (see also [Supplementary Figure S1](#SD1){ref-type="supplementary-material"}). [Figure 1](#F1){ref-type="fig"} shows the 'Manhattan' plot of the association results across the autosomal genome and [Table 1](#T1){ref-type="table"} reports the association between single SNPs and OCD with *P*\<1×10^−5^. No marker tested for association met the standard of genome-wide significance. The smallest *P*-value for our study was observed with a marker on chromosome 9 (rs4401971) at a *P*-value of 4.13×10^−7^. This SNP is 1.28 Mb from the 5′ end of the *protein tyrosine phosphatase, receptor type, D* gene (*PTPRD,* isoform 1; according to RefSeq). The second most significantly associated SNP (rs6876547, *P*=1.76×10^−6^) is located in a region of cadherin clusters and it is of note, that a second, independent SNP (rs6452234, *P*=1.13×10^−5^, r^2^\<0.2, distance \~650kb) is located in the same region. The nearest flanking protein coding genes are the *cadherin 9, type 2* (*CDH9*, 1 308 kb) and the *cadherin 10, type 2* (*CDH10*, 927 kb) genes. A 'regional association plot' of these two top regions is provided in [Figure 2](#F2){ref-type="fig"}.

We used the single-maker association signals to follow up the results from the recent IOCDF-GC GWAS ^[@R21]^. For the markers listed in [Table 1](#T1){ref-type="table"} of that study, we found evidence for association with a marker (rs2205748, same effect allele and direction of effect) on chromosome 6 near the genes *GRIK2* (distance to gene 1.94 Mb) and the *HECT domain and ankyrin repeat containing E3 ubiquitin protein ligase 1* gene (*HACE1,* 713 kb) with an uncorrected *P-*value of 0.0493 in our study (*P*=8.52×10^−6^ in the original IOCDF-GC trio-case-control analysis). One additional region (harboring the gene for the *cAMP-specific phosphodiesterase 4D*, *PDE4D*) showed a nominal significant signal; however, the effect (based on the same effect allele) was in the opposite direction (compared with the IOCDF-GC finding). Though no other marker among the tested SNPs from the IOCDF-GC GWAS reached a significant result, it is of note that, for the region around *DLGAP1* an independent SNP in our analyses (rs3866988) yielded a *P*-value of 2.67×10^−4^ and thus indicating this region as a susceptibility factor for OCD (r^2^=0.023, D′=0.316 between rs3866988 and rs11081062/ rs11663827, based on 1 000 genomes data). It is also of note, that 12 out of 15 markers (counting the *DLGAP1* markers in perfect LD only once) show the same direction of effects for the effect alleles in both the IOCDF-GC and OCGAS analyses (binominal test with probability 0.5 = sign test: *P*=0.0176). Detailed results for the follow-up of the IOCDF-GC results are found in [Table 2](#T2){ref-type="table"}.

Gene-based findings {#S8}
-------------------

Gene-based analyses for 21 567 genes (protein-coding genes and miRNAs) resulted in an experiment-wise significant result for two genes, the *IQ motif containing K* gene (*IQCK*) and the *chromosome 16 open reading frame 88* gene (*C16orf88; P*~corr~\<0.0215; *P*\<1×10^−6^). Both genes are located in the same chromosomal region (16p12.3) and share their leading SNP, i.e. the SNP with the lowest *P*-value that is annotated to the gene (rs1544352; *P*=1.94×10^−5^). The only other gene that shows a *P*-value \< 1×10^−4^ is the *orofacial cleft candidate1* gene (*OFCC1*; P=6.29×10^−5^). A more detailed list of association results for the gene-based analyzes are given in [Table 3](#T3){ref-type="table"} and a 'regional association plot' for the *OFCC1* locus is provided in [Figure 2](#F2){ref-type="fig"}.

Query of the interactome ^[@R34]^ for high confidence interactors of *DLGAP1* and *GRIK2* identified 169 interactors of *DLGAP1* and 161 interactors for *GRIK2* (246 interactors for both of them together). Gene-based analyses revealed that 21 (out of 246) genes showed a nominal significant *P*-value (one-sided *P*=0.075). This included 16 genes for *DLGAP1* (one-sided *P*=0.069) and 14 genes for *GRIK2* (one-sided *P*=0.135). It is of note that *GRIK2* itself was identified as interactor of *DLGAP1* and showed a nominal significant gene-based *P*-value of 0.03. Among the list of other nominal significant genes are the *neuronal differentiation 6* gene (*NEUROD6, P*=0.010), the *synaptic vesicle glycoprotein 2A* gene (*SV2A, P*=0.026), the *ionotropic, AMPA 4 glutamate receptor* gene (*GRIA4, P*=0.039), and the solute carrier family 1 (glial high affinity glutamate transporter), member 2 gene (*SLC1A2*, *P*=0.035). A full list of these results is given in [Supplementary Table S4](#SD2){ref-type="supplementary-material"}.

We also attempted to replicate a reported enrichment of association signals for two gene sets that comprised high confidence targets of two miRNA families (see the Stewart et al OCD GWAS). Analyses of the miRNA families of predicted miR-130ac/301ab/301b/301b-3p/454/721/4295/3666 (miRNA set 1) and miRNA-219-5p/508/508-3p/4782-3p (miRNA set 2) targets showed nominal significance for 3 out of 45 high confidence targets in miRNA set 1 and 14 out of 145 high confidence targets in miRNA set 2. The number of nominal significant genes for both sets are higher then expected by chance; however, for both sets, no significant enrichment for OCD associated genes was found in either set (one-sided *P*=0.323 and one-sided *P*=0.087, respectively). It is of note that one of the high confident targets in miRNA set 2 (the *epiregulin* gene, *EREG*) did demonstrate an experiment-wise significance level (correcting for the number of tests performed in miRNA set2; *P*=3.06×10^−4^; *P*~corr~=0.044).

Discussion {#S9}
==========

Here we report the results of a GWAS including a sample of 1 406 patients with OCD, that was predominantly family-based, but which also included a case-control subsample to increase power (resulting in a total sample of 5 061 individuals). The study identified interesting candidate genes for OCD, but failed to detect any genome-wide significant findings. This is similar to what has been observed for other psychiatric phenotypes such as schizophrenia, for which genome-wide significant findings were only achieved after either starting with more samples in the discovery step ^[@R35],\ [@R36]^ or making use of large follow-up samples, that were orders of magnitude larger then the original discovery samples ^[@R37],\ [@R38]^. We suspect that, with additional samples, the findings of genetic studies for OCD will be more robust, and our currently suggestive findings may reach genome-wide significance.

Of particular interest is the signal near the *PTPRD* gene (rs4401971), the most significant found in this study (*P*=4.13×10^−7^). PTPRD is a member of the receptor protein tyrosine phosphatase family, which comprises transmembrane signaling molecules that regulate a variety of cellular processes including cell growth and differentiation ^[@R39]^. Pre-synaptic *PTPRD* promotes the differentiation of glutamatergic synapses ^[@R40]--[@R43]^ and interacts with Slit and NTRK-like family member 3 (*SLITRK3*) which acts as a postsynaptic adhesion molecule. Together both proteins selectively regulate inhibitory GABAergic synapse development ^[@R44]^. This is interesting because molecules in the same family, *SLITRK5* and *SLITRK1*, have been shown to be associated with TS and OCD, the former in a mouse model and the latter in a TS genetic study ^[@R45],\ [@R46]^.

Mice deficient in PTPRD show impairment in learning and memory tasks, especially spatial learning, and exhibit enhanced long-term potentiation (LTP), a form of activity dependent plasticity ^[@R47]^. This is relevant to OCD, in that memory deficits have been reported for this condition ^[@R48]^. PTPRD also has been shown to be associated with restless leg syndrome (RLS) ^[@R49]^ and hemizygous deletions were detected in four unrelated attention deficit hyperactivity disorder (ADHD) probands ^[@R50]^.

Our second strongest association finding is located in a region of cadherin clusters. It is known that CDH9 has been reported associated with OCD ^[@R51]^. Furthermore, six SNPs between cadherin 10 (*CDH10*) and cadherin 9 (*CDH9*) were significantly (as well as in a replication sample) associated with autism spectrum disorders (ASD) ^[@R52]^ and was a top (although not significant) association signal in anorexia nervosa ^[@R53]^.

Analysis of previously identified GWAS hit regions for the IOCDF-GC study ^[@R21]^ revealed that 12 out of the 15 strongest signals in that study showed associations with the same direction of effects (based on the same effect alleles) in both the IOCDF-GC and OCGAS analyses (sign test *P*=0.0176). This observation supports the hypothesis that future collaborative studies (meta- and mega-analyses) will be able to identify OCD genes at the level of genome-wide significance. Support for association with OCD was particularly found in two previously identified genetic regions (see above). The most interesting region harbors the *DLGAP1* gene. In the IOCDF-GC study signals in this gene were the top signals from the case-control analysis. Although the specific SNP from the former study was not found significant in this study, there was a prominent signal for an independent nearby marker (*P*=2.67×10^−4^). This observation potentially serves as independent evidence for association of markers in this region. *DLGAP1* is a member of the neuronal postsynaptic density complex and is in the same family as the *DLGAP3* gene, which has been shown in a convincing way to be responsible for OCD-like behaviors in *DLGAP3* knockout mice models ^[@R54]^. A marker in the second genetic region (harboring *GRIK2*), also a top signal in the IOCDF-GC GWAS showed nominal significance in our study (*P*=0.045). Although failing to reach experiment-wise significance it is of note that *DLGAP1* and *GRIK2* interact (FUNCOUP ^[@R34]^). Following up these signals in a gene-set analysis for high confidence interaction partners of *DLGAP1* and *GRIK2* (identified using FUNCOUP ^[@R34]^) showed a trend for association and pointed to a potential role of a set of *DLGAP1* and *GRIK2* interactors in the etiology of OCD, involving genes such as *NEUROD6*, *SV2A*, *GRIA4*, and *SLC1A2*. Interestingly *PTPRD* was part of this gene set. It is of note that for both *DLGAP1* and *GRIK2* we identified more then 160 interactors each, thus indicating they are highly connected nodes (hubs) in the interactome. Earlier findings have suggested that only genes that are essential in (early) development ("essential genes") tend to encode hub proteins, while the vast majority of disease genes are nonessential and show no tendency to encode hub proteins ^[@R55]^. This might point to *DLGAP1* and GRIK2 as being essential genes in early (neuro-)development. However, more studies are warranted to confirm this hypothesis.

Gene-based association analyses identify significant signals in two genes, *IQCK* and *C16orf88*; however, this finding is not amenable to interpretation at this time. The next strongest gene-based signal in *OFCC1* is intriguing because a variant within the exon of this gene has been reported in seven affected individuals of family segregating OCD, TS, and ADHD ^[@R56]^.

This study employed careful and comprehensive phenotyping; MD and PhD-trained psychologists conducted all assessments and recruitment sites used the same assessment approach and all cases were reviewed at a single site (JHU) to ensure diagnostic replicability. Given the likely etiologic heterogeneity of OCD, the comprehensive phenotyping provides opportunities for future studies (through subtyping based e.g. on factor-analytical approaches).

A limitation of this study is that the power to detect significant association signals for small effect sizes is limited by the sample size. This has been clearly demonstrated in many GWAS efforts for other neuropsychiatric conditions (e.g., schizophrenia) in which studies of comparable size have failed to identify significant association signals. Yet, when sample sizes have increased (in some case 10 or more fold), then multiple significant signals were identified. Power was improved in this study by using a hybrid analytic approach that included both family and case-control samples in the analysis. In conclusion, while this OCD GWAS study did not identify a study-wide significant association finding, several of the strongest findings are particularly interesting. There are both plausible biologic hypotheses and prior genetic evidence, for either OCD or related conditions, for the two most significant association findings, *PTPRD* and *CDH9/CDH10.* The finding that the signals in this GWAS concur with respect to allele and direction significantly with the top signals in a second reported OCD GWAS, suggests that similar genetic underpinnings of OCD are identified in both studies. Moreover, while not a replication in the full sense, findings for the genes *DLGAP1* and *GRIK2* suggest that they are both relevant candidates genes for OCD. The suggestive findings in this study await replication in larger samples.
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======================
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![Manhattan plot for OCGAS GWAS\
Shown are the result for the hybrid analysis of the within and between family component of the OCGAS GWAS. A thin blue line indicates level of suggestive evidence for association (1 × 10^−5^) and a thin red line indicates genome-wide significance (5 × 10^−8^).](nihms580426f1){#F1}

###### Regional association plots for top regions in OCGAS GWAS

The most associated marker in the region (see [table 2](#T2){ref-type="table"} and [S2](#SD2){ref-type="supplementary-material"}, purple dot) is centered in a genomic window of 5 Mb (hg19). P-values for the OCGAS GWAS are given. The linkage disequilibrium (LD) strength (r^2^; data from the 1000 genomes project European samples) between the sentinel single nucleotide polymorphism and its flanking markers is demonstrated by the coloring of the dots for the neighboring markers (ranging from red = high to blue = low). The recombination rate (cM/Mb; second y axis) is plotted in blue. Plots are given for the a) chromosome 9 region harboring *PTPRD* (clump 1 in [table 2](#T2){ref-type="table"}), b) the chromosome 5 region (clump 2 in [table 2](#T2){ref-type="table"}), and c) the chromosome 16 region harboring the two genes that were identified in the gene-based analysis, *IQCK* and *C16orf88*.
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###### Results for OCGAS GWAS

SNPs listed are strongest associated GWAS variants (*P* \< 0.0001) in the hybrid analysis of the within and between family component. Only one SNP ("lead SNP" = SNP with lowest p-value) per clump is given. Clumps are defined using PLINK (\--clump-p1 0.0001, \--clump-p2 0.05, \--clump-r2 0.20, \--clump-kb 5000, LD based on additional controls that have also been used for the hybrid analysis). Headings are as follows: MARKERINFO (\# - Rank place for clump for which this SNP is the lead SNP; CHR -- Chromosome; SNP -- marker name for lead SNP in clump; BP -- position; MA -- minor allele in additional controls; MAF -- frequency of this SNP in additional controls;), OCGAS (INFO -- number of informative families in the within family component analysis; DIR -- direction of effect with respect to the MA; P -- p-value for the lead SNP in the clump; N -- number of additional SNPs in the clump meeting the aforementioned criteria), and ANNOTATION (GENE -- gene in which lead SNP is physically located; LEFT GENE and RIGHT GENE -- nearest flanking genes).

  MARKERINFO   OCGAS   ANNOTATION                                                                                                     
  ------------ ------- ------------- ------------ ----- -------- ------- ------ --------------------- ------ --------- -------------- --------------
  1            9       rs4401971     11890045     A     0.41     619     − −    4.13 × 10^−7^         31     NA        LOC646114      LOC100049717
  2            5       rs6876547     25572301     G     0.19     471     ++     1.76 × 10^−6^         6      NA        CDH10          MSNL1
  3            7       rs1343795     54313171     A     0.08     229     − −    9.69 × 10^−6^         6      NA        FLJ45974       LOC222005
  4            5       rs6452234     24922789     A     0.21     429     − −    1.13 × 10^−5^         10     NA        CDH10          MSNL1
  5            14      rs1014951     24039559     T     0.1      311     ++     1.49 × 10^−5^         6      JPH4      LOC100131731   DHRS2
  6            8       rs7462051     80266553     A     0.18     462     ++     1.69 × 10^−5^         21     NA        IL7            LOC100128963
  *7*          *16*    *rs1544352*   *19713882*   *C*   *0.16*   *445*   *++*   *1.94* × 10^−^*^5^*   *19*   NA        C16orf62       C16orf88
  8            4       rs1532154     157279663    C     0.21     427     − −    2.22 × 10^−5^         3      NA        FTHP2          hCG_1814936
  9            11      rs509876      79811268     G     0.13     406     ++     2.29 × 10^−5^         4      NA        LOC646112      LOC729790
  10           20      rs10392       37550935     A     0.19     467     − −    2.87 × 10^−5^         18     PPP1R16   ACTR5          FAM83D
  11           9       rs2821204     11683901     G     0.2      492     ++     2.89 × 10^−5^         29     NA        LOC646114      LOC100049717
  12           10      rs1088258     97109019     A     0.33     577     − −    3.56 × 10^−5^         22     SORBS1    PDLIM1         LOC643981
  13           8       rs2278144     25634077     T     0.13     382     − −    3.94 × 10^−5^         2      NA        CDCA2          EBF2
  14           15      rs8026755     37247722     A     0.33     594     − −    4.03 × 10^−5^         8      MEIS2     LOC145845      LOC390576
  15           3       rs838209      176352763    C     0.34     616     − −    4.14 × 10^−5^         5      NA        LOC730168      TBL1XR1
  16           5       rs1773562     168653502    C     0.1      312     ++     5.03 × 10^−5^         4      SLIT3     LOC728095      CCDC99
  17           8       rs7003102     126303493    G     0.14     416     ++     5.14 × 10^−5^         6      NSMCE2    KIAA0196       TRIB1
  18           8       rs1254734     26833198     A     0.2      486     − −    5.38 × 10^−5^         11     NA        LOC100127897   LOC100132229
  19           2       rs7593878     44358504     C     0.15     378     − −    5.44 × 10^−5^         6      NA        LRPPRC         PPM1B
  20           2       rs1686740     182189405    T     0.11     345     ++     6.10 × 10^−5^         5      NA        LOC729026      LOC100127923
  21           13      rs9541148     35095884     C     0.37     624     − −    6.73 × 10^−5^         5      NA        LOC100130499   LOC100129452
  22           18      rs1671253     50040561     T     0.29     555     − −    7.04 × 10^−5^         19     DCC       LOC100132995   LOC100133176
  23           6       rs973714      133578733    A     0.34     615     ++     7.44 × 10^−5^         12     EYA4      LOC285735      TCF21
  24           10      rs3902042     17065067     T     0.39     641     ++     7.71 × 10^−5^         12     CUBN      RSU1           TRDMT1
  25           20      rs8120171     50712059     T     0.19     414     − −    7.85 × 10^−5^         1      ZFP64     SALL4          ERP28P
  26           4       rs1685101     75216365     A     0.24     467     − −    7.89 × 10^−5^         15     NA        EPGN           EREG
  28           3       rs9845643     179531062    G     0.2      457     − −    8.58 × 10^−5^         7      PEX5L     USP13          LOC647249
  29           9       rs1126590     92077132     C     0.39     634     − −    8.60 × 10^−5^         12     SEMA4D    PA2G4P6        LOC100128670
  30           20      rs1699787     16533162     C     0.23     518     ++     8.68 × 10^−5^         12     KIF16B    LOC100131642   RPLP0P1
  31           9       rs2183738     71211200     G     0.14     366     ++     8.73 × 10^−5^         8      NA        C9orf71        LOC347097
  32           1       rs1209698     185201061    C     0.34     612     ++     8.87 × 10^−5^         32     C1orf26   LOC100129295   IVNS1ABP
  33           8       rs7005206     130620813    A     0.15     377     − −    9.13 × 10^−5^         7      NA        LOC100129525   LOC100130376

###### Follow up of IOCDF-GC GWAS results

SNPs listed are strongest associated GWAS variants in trio, case-control and combined trio-case-control samples reported in table 1 of Stewart et al. 2013. Only the results from the trio-case-control sample are listed in the table (IOCDF --GC: P) along the results from the current GWAS (OCGAS: P). Directions of effects (IOCDF-GC: DIR and OCGAS: DIR) are given based on the A1 alleles in the IOCF analyses (IOCDF-GC: A1). For the IOCDF-GC GWAS directions are given for all study samples (EU, AJ, SA, trios). In case of the OCGAS GWAS the directions refer to the combined results (within and between family component). For SNPs not present in the OCGAS results a proxy SNP was used that was identified using the SNAP tool (OCGAS: PROXY; max distance to query SNP 500kb, rsq min 0.8, reference data: 1000 genomes project pilot 1 release).

  MARKERINFO      IOCDF-GC   OCGAS           GENES (kb)                                                                   
  --------------- ---------- --------------- -------------- --------- ---------- ------------ ------- ------------------- -------------------------------
  rs11898020      2          144282078       2.65E-04       A/G       +−+ −      0.6357       −       N/A                 ARHGAP15 (intronic)
  rs10165908      2          158315629       0.0169         C/T       +++−       0.5816       \+      rs2198581 (0.83)    CYTIP (15), ACVR1C (68)
  rs1838733       5          58533392        3.82E-05       T/C                  0.0482       \+      rs6858946 (0.95)    PDE4D (intronic)
  rs26728         5          106946056       1.01E-04       T/C       −++ −      0.3289       −       rs154191 (0.85)     EFNA5 (intronic)
  rs4868342       5          173504522       3.20E-05       C/T       ++++       0.8425       −       N/A                 HMP19 (intronic)
  rs9499708       6          104445367       2.96E-06       C/T       − −+ −     0.1287       −       N/A                 GRIK2 (1927), HACE1 (731)
  **rs2205748**   **6**      **104462555**   **8.52E-06**   **G/A**   **++++**   **0.0493**   **+**   **N/A**             **GRIK2 (1944), HACE1 (713)**
  rs182320        6          130073291       2.25E-05       C/T       ++++       0.5801       \+      N/A                 ARHGAP18 (42), C6orf191 (79)
  rs6531002       8          12722703        0.0067         T/C       −++ −      0.4897       −       rs7823534 (0.96)    LONRF1 (110), KIAA1456 (80)
  rs11611761      12         33025612        0.115          A/C       − −+ −     0.2676       −       rs17543624 (0.87)   PKP2 (intronic)
  rs297941        12         50319086        4.99E-07       G/A                  0.8846       −       N/A                 FAIM2 (21), AQP2 (25)
  rs9652236       13         72688774        5.14E-06       T/G       ++++       0.4017       \+      N/A                 DACH1 (247), MZT1 (594)
  rs11081062      18         3662879         2.92E-05       T/C       +0++       0.6274       \+      N/A                 DLGAP1 (intronic)
  rs11663827      18         3663631         2.31E-05       A/G       ++++       0.6844       \+      N/A                 DLGAP1 (intronic)
  rs485186        19         49207206        9.94E-06       G/A       ++++       0.5067       \+      N/A                 FUT2 (coding-synon)
  rs6131295       20         11996267        3.63E-05       G/A       \+         0.5663       −       N/A                 BTBD3 (89), SPTLC3 (993)

###### Gene-based results

Genes listed are strongest associated protein-coding genes in the FORGE analysis (*P* \< 0.001). Annotation information is taken from ENSEMBL v70 (GENEINFO: CHR, START, STOP), gene names (GENEINFO: GENE) are following HGNC nomenclature. The results (ASSOCIATION: P -- gene-based p-value; P_CORR -- experiment-wise corrected gene-based p-value; N -- number of SNPs annotated to the gene; minP -- p-value of SNP with lowest p-value that was annotated to the gene) are based on the Z_FIX statistic as implemented into FORGE. Annotation used a +/− 20kb (from GENEINFO: START and STOP) flanking region for each gene under study.

  GENEINFO   ASSOCIATION                                                   
  ---------- ------------- ----------- ---------- ---------- ------- ----- ----------
  16         19714902      19729557    C16orf88   9.99E-07   0.019   7     1.94E-05
  16         19727778      19868907    IQCK       9.99E-07   0.019   20    1.94E-05
  6          9596343       10211841    OFCC1      6.29E-05   1       152   2.86E-04
  14         24037244      24048009    JPH4       1.16E-04   1       5     1.49E-05
  15         79252289      79383115    RASGRF1    1.18E-04   1       53    6.25E-04
  19         2100988       2164464     AP3D1      1.96E-04   1       17    1.93E-03
  9          116148597     116163613   ALAD       2.56E-04   1       23    9.83E-03
  1          185087220     185126204   TRMT1L     2.93E-04   1       9     1.73E-04
  4          75230860      75254468    EREG       3.06E-04   1       19    7.89E-05
  20         37590942      37668366    DHX35      3.55E-04   1       7     6.22E-05
  6          88117701      88221352    C6orf165   3.55E-04   1       15    1.84E-03
  15         41186628      41196173    VPS18      4.36E-04   1       6     1.02E-03
  1          185126212     185260897   SWT1       5.00E-04   1       22    8.87E-05
  6          88180341      88222054    SLC35A1    6.11E-04   1       10    1.84E-03
  1          244571796     244615436   ADSS       6.30E-04   1       14    2.49E-04
  9          97418353      97480105    C9orf118   6.32E-04   1       16    4.96E-04
  9          71939488      72007371    FAM189A2   6.47E-04   1       18    9.37E-04
  3          149191761     149221068   TM4SF4     6.67E-04   1       23    6.00E-04
  10         97071528      97321171    SORBS1     6.84E-04   1       86    1.34E-04
  16         19566562      19718115    C16orf62   7.54E-04   1       37    1.94E-05
  19         19287712      19303425    MEF2BNB    8.09E-04   1       11    8.85E-04
  10         90562654      90580303    LIPM       8.46E-04   1       21    2.73E-03
  14         24025216      24029480    THTPA      8.90E-04   1       8     1.49E-05
  1          204042243     204096863   SOX13      9.17E-04   1       37    1.57E-03
  1          231359509     231376933   C1orf131   9.33E-04   1       15    4.05E-03
  6          133561736     133853258   EYA4       1.00E-03   1       84    7.44E-05
